Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$10.48
▼ $0.22 (-2.1%)
Market data updated: 09/20 03:03 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$1.48B
Day Range
$10.41 - $10.67
52-Week Range
$7.71 - $15.48
Beta
—
Next Earnings
10.11.2026
Support
$9.01
Resistance
$11.89
ARDT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-21.3% (1Y)
Strengths: 5/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 1.97
Risk
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.29 (3y annualized return -17.9% / max drawdown 61.2%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
50
Value
55
Momentum
33
Risk
48
Sentiment
100
Fundamental
53
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Ardent Health, Inc. has centered on its financial performance and market outlook, with key themes including **weaker Q2 2026 earnings and downward guidance**, prompting investor scrutiny. Analysts like RBC Capital maintained an **Outperform rating** while raising their price target, though some platforms flagged the stock as a **strong sell**. The company also highlighted **expansion in specialty care**, such as partnerships with the UT Tyler School of Medicine, and **cardiovascular advancements** through the Oklahoma Heart Institute. Share buybacks and volatility in stock options were additional focal points.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Ardent Health, Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
38
Psychology
43
Fundamentals
53
Technical
33
Valuation
55
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+18%
Market Narrative
59
Fundamental Reality
38
Narrative Gap
+21
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ARDT’s psychology is dominated by **euphoria**, as extreme positive sentiment, strong momentum, and a 10.2% premium over the 200-day average create an inflated narrative gap (67 vs. 38). Overconfidence (8) lingers due to price outperforming fundamentals, while FOMO (17) reflects momentum-driven buying. The key question: *Is this euphoria justified by fundamentals, or is it a speculative bubble?* Low volatility and peer underperformance further suggest traders are chasing gains rather than hedging. The absence of panic or anchoring implies confidence remains high, but the gap warns of potential dissonance if reality diverges.
Updated: 09/06/2026, 04:42 AM
What could change this?
👥 What the crowd believes
"RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with an Outperform and raises the price target from $12 to $13"
"Ardent Health reported second quarter 2026 results... with net income and earnings per share lower than a year earlier and full year earnings guidance reduced"
"ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 93/100
🔴 Weakest match
Philip Fisher — 14/100
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 93
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 77
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 73
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 62
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 52
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 43
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 38
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 37
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 28
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 27
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 18
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 18
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 14
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
2.1%
EBITDA Margin
—
ROE
10.5%
ROA
2.6%
ROIC
—
EPS
$0.96
Cash
$709.60M
Total Debt
$1.10B
Current Ratio
1.97
Debt/Equity
0.85
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$9.10
Tangible Book Value per Share (Tangible NAV)
$2.80
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 11.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Yahoo · 27.8.2026
Business Wire · 27.8.2026
Zacks · 13.8.2026
Motley Fool · 11.8.2026
Business Wire · 11.8.2026
Benzinga · 10.8.2026
Simply Wall St. · 8.8.2026
Yahoo · 8.8.2026
Zacks · 7.8.2026
Yahoo · 7.8.2026
Benzinga · 6.8.2026
Benzinga · 6.8.2026
GuruFocus.com · 5.8.2026
Yahoo · 5.8.2026
Ardent Health, Inc. (ARDT) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ARDT currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ARDT's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 1.97; Price is above the 200-day average; +15.6% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Calmar: -0.29 (3y annualized return -17.9% / max drawdown 61.2%); Earnings per share (EPS) growth: -39.2%; Net income growth: -35.4%.
StockIQ has no recorded dividend payment history for ARDT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 4 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Caspers Dave | Grant/Award from Employer | 1.7.2026 | 103,653 | +103,653 | — |
| Caspers Dave | Grant/Award from Employer | 1.7.2026 | 174,930 | +103,653 | — |
| DeMichiei Robert | Open Market Purchase | 5.6.2026 | 11,260 | +11,260 | $8.73 |
| LUMSDAINE ALFRED | Open Market Purchase | 5.6.2026 | 10,000 | +10,000 | $8.81 |
| LUMSDAINE ALFRED | Open Market Purchase | 5.6.2026 | 329,183 | +10,000 | $8.81 |
| DeMichiei Robert | Open Market Purchase | 5.6.2026 | 35,564 | +11,260 | $8.73 |
| DeMichiei Robert | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| GOODYEAR WILLIAM M | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| BYNOE PETER C B | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Robinson Edmondo | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Campion Suzanne | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Webb Robert Thomas | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Sen Rahul | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Petrovich Stephen C. | Grant/Award from Employer | 1.4.2026 | 24,904 | +24,904 | — |
| Havdala Ellen | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Sotir Mark R | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Caspers Dave | Tax Withholding in Shares | 1.4.2026 | 2,684 | -2,684 | $8.67 |
| Petrovich Stephen C. | Tax Withholding in Shares | 1.4.2026 | 1,808 | -1,808 | $8.67 |
| Bulgarelli Peter J. | Grant/Award from Employer | 1.4.2026 | 14,231 | +14,231 | — |
| Caspers Dave | Grant/Award from Employer | 1.4.2026 | 35,673 | +35,673 | — |
| GOODYEAR WILLIAM M | Grant/Award from Employer | 1.4.2026 | 115,367 | +14,231 | — |
| LUMSDAINE ALFRED | Tax Withholding in Shares | 1.4.2026 | 265,337 | -4,381 | $8.67 |
| LUMSDAINE ALFRED | Grant/Award from Employer | 1.4.2026 | 319,183 | +53,846 | — |
| BYNOE PETER C B | Grant/Award from Employer | 1.4.2026 | 115,367 | +14,231 | — |
| Havdala Ellen | Grant/Award from Employer | 1.4.2026 | 115,367 | +14,231 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,899,665 shares short as of 2026-08-31 · vs. 4,320,076 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
51.0% of trading volume this week was short selling, vs. 48.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology